Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Clinical Genetics
|
March 17, 2017
Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers
M Muller, S Ferlicot, M Guillaud-Bataille, et al.
ESMO Open
|
April 26, 2021
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
T K Choueiri, J Larkin, S Pal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial
C Suarez, C Rojas, S J Shin, et al.
International Urology and Nephrology
|
April 13, 2019
Long-term oncological outcomes of cystic renal cell carcinoma according to the Bosniak classification
R Boissier, I Ouzaid, F X Nouhaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study
R J Motzer, L Albiges, S A Treviño Aguirre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T K Choueiri, R J Motzer, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 8, 2017
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
P Schöffski, A Wozniak, B Kasper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2024
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
L Albiges, M T Bourlon, M Chacón, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2026
Corrigendum to 'Subcutaneous versus intravenous nivolumab for renal cell carcinoma': [Annals of Oncology volume 36 (2025) 99-107]
L Albiges, M T Bourlon, M Chacón, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2024
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
T K Choueiri, K Penkov, H Uemura, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Clinical Genetics
|
March 17, 2017
Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers
M Muller, S Ferlicot, M Guillaud-Bataille, et al.
ESMO Open
|
April 26, 2021
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
T K Choueiri, J Larkin, S Pal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial
C Suarez, C Rojas, S J Shin, et al.
International Urology and Nephrology
|
April 13, 2019
Long-term oncological outcomes of cystic renal cell carcinoma according to the Bosniak classification
R Boissier, I Ouzaid, F X Nouhaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 20, 2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study
R J Motzer, L Albiges, S A Treviño Aguirre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T K Choueiri, R J Motzer, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 8, 2017
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
P Schöffski, A Wozniak, B Kasper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2024
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
L Albiges, M T Bourlon, M Chacón, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2026
Corrigendum to 'Subcutaneous versus intravenous nivolumab for renal cell carcinoma': [Annals of Oncology volume 36 (2025) 99-107]
L Albiges, M T Bourlon, M Chacón, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2024
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
T K Choueiri, K Penkov, H Uemura, et al.
Page
of 7